nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—CHRM3—ureter—prostate cancer	0.0639	0.535	CbGeAlD
Trihexyphenidyl—CHRM5—epithelium—prostate cancer	0.0098	0.082	CbGeAlD
Trihexyphenidyl—CHRM2—prostate gland—prostate cancer	0.00915	0.0766	CbGeAlD
Trihexyphenidyl—CHRM1—prostate gland—prostate cancer	0.00833	0.0697	CbGeAlD
Trihexyphenidyl—CHRM4—testis—prostate cancer	0.00752	0.0629	CbGeAlD
Trihexyphenidyl—CHRM3—prostate gland—prostate cancer	0.00746	0.0624	CbGeAlD
Trihexyphenidyl—CHRM3—renal system—prostate cancer	0.00508	0.0425	CbGeAlD
Trihexyphenidyl—CHRM3—urethra—prostate cancer	0.00499	0.0418	CbGeAlD
Trihexyphenidyl—Tension—Estradiol valerate/Dienogest—prostate cancer	0.00369	0.00591	CcSEcCtD
Trihexyphenidyl—Nervousness—Estradiol valerate/Dienogest—prostate cancer	0.00365	0.00585	CcSEcCtD
Trihexyphenidyl—Vision blurred—Degarelix—prostate cancer	0.00337	0.0054	CcSEcCtD
Trihexyphenidyl—CHRM3—testis—prostate cancer	0.00329	0.0275	CbGeAlD
Trihexyphenidyl—Confusional state—Flutamide—prostate cancer	0.00328	0.00525	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Goserelin—prostate cancer	0.00326	0.00522	CcSEcCtD
Trihexyphenidyl—Weight decreased—Ethinyl Estradiol—prostate cancer	0.00317	0.00508	CcSEcCtD
Trihexyphenidyl—Dry skin—Goserelin—prostate cancer	0.00306	0.0049	CcSEcCtD
Trihexyphenidyl—Constipation—Abiraterone—prostate cancer	0.00306	0.0049	CcSEcCtD
Trihexyphenidyl—Memory impairment—Capecitabine—prostate cancer	0.0029	0.00464	CcSEcCtD
Trihexyphenidyl—Somnolence—Flutamide—prostate cancer	0.00289	0.00463	CcSEcCtD
Trihexyphenidyl—Delusion—Prednisone—prostate cancer	0.00286	0.00458	CcSEcCtD
Trihexyphenidyl—Blindness—Epirubicin—prostate cancer	0.00286	0.00458	CcSEcCtD
Trihexyphenidyl—Tension—Bicalutamide—prostate cancer	0.00284	0.00454	CcSEcCtD
Trihexyphenidyl—Nervousness—Bicalutamide—prostate cancer	0.00281	0.00449	CcSEcCtD
Trihexyphenidyl—Constipation—Nilutamide—prostate cancer	0.00279	0.00447	CcSEcCtD
Trihexyphenidyl—Constipation—Flutamide—prostate cancer	0.00278	0.00445	CcSEcCtD
Trihexyphenidyl—Confusional state—Cabazitaxel—prostate cancer	0.00277	0.00444	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Nilutamide—prostate cancer	0.00269	0.00431	CcSEcCtD
Trihexyphenidyl—Tachycardia—Cabazitaxel—prostate cancer	0.00268	0.0043	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Flutamide—prostate cancer	0.00268	0.00429	CcSEcCtD
Trihexyphenidyl—Blindness—Doxorubicin—prostate cancer	0.00265	0.00424	CcSEcCtD
Trihexyphenidyl—Memory impairment—Prednisone—prostate cancer	0.00258	0.00413	CcSEcCtD
Trihexyphenidyl—Drowsiness—Goserelin—prostate cancer	0.00257	0.00412	CcSEcCtD
Trihexyphenidyl—Asthenia—Abiraterone—prostate cancer	0.00257	0.00411	CcSEcCtD
Trihexyphenidyl—Constipation—Degarelix—prostate cancer	0.0025	0.004	CcSEcCtD
Trihexyphenidyl—Dry skin—Estradiol—prostate cancer	0.00243	0.00388	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Degarelix—prostate cancer	0.00241	0.00385	CcSEcCtD
Trihexyphenidyl—Confusional state—Bicalutamide—prostate cancer	0.00238	0.00381	CcSEcCtD
Trihexyphenidyl—Constipation—Cabazitaxel—prostate cancer	0.00235	0.00376	CcSEcCtD
Trihexyphenidyl—Asthenia—Nilutamide—prostate cancer	0.00234	0.00375	CcSEcCtD
Trihexyphenidyl—Vomiting—Estramustine—prostate cancer	0.00234	0.00375	CcSEcCtD
Trihexyphenidyl—Asthenia—Flutamide—prostate cancer	0.00233	0.00374	CcSEcCtD
Trihexyphenidyl—Dizziness—Estrone—prostate cancer	0.00233	0.00372	CcSEcCtD
Trihexyphenidyl—Rash—Estramustine—prostate cancer	0.00232	0.00372	CcSEcCtD
Trihexyphenidyl—Dermatitis—Estramustine—prostate cancer	0.00232	0.00371	CcSEcCtD
Trihexyphenidyl—Headache—Estramustine—prostate cancer	0.00231	0.00369	CcSEcCtD
Trihexyphenidyl—Vomiting—Abiraterone—prostate cancer	0.00227	0.00364	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Cabazitaxel—prostate cancer	0.00227	0.00363	CcSEcCtD
Trihexyphenidyl—Rash—Abiraterone—prostate cancer	0.00226	0.00361	CcSEcCtD
Trihexyphenidyl—Dermatitis—Abiraterone—prostate cancer	0.00225	0.00361	CcSEcCtD
Trihexyphenidyl—Vomiting—Estrone—prostate cancer	0.00224	0.00358	CcSEcCtD
Trihexyphenidyl—Rash—Estrone—prostate cancer	0.00222	0.00355	CcSEcCtD
Trihexyphenidyl—Dermatitis—Estrone—prostate cancer	0.00222	0.00355	CcSEcCtD
Trihexyphenidyl—Headache—Estrone—prostate cancer	0.0022	0.00353	CcSEcCtD
Trihexyphenidyl—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.0022	0.00353	CcSEcCtD
Trihexyphenidyl—Nausea—Estramustine—prostate cancer	0.00219	0.0035	CcSEcCtD
Trihexyphenidyl—Dizziness—Nilutamide—prostate cancer	0.00216	0.00346	CcSEcCtD
Trihexyphenidyl—Dizziness—Flutamide—prostate cancer	0.00215	0.00344	CcSEcCtD
Trihexyphenidyl—Somnolence—Bicalutamide—prostate cancer	0.0021	0.00336	CcSEcCtD
Trihexyphenidyl—Asthenia—Degarelix—prostate cancer	0.00209	0.00335	CcSEcCtD
Trihexyphenidyl—Nausea—Estrone—prostate cancer	0.00209	0.00334	CcSEcCtD
Trihexyphenidyl—Vomiting—Nilutamide—prostate cancer	0.00208	0.00333	CcSEcCtD
Trihexyphenidyl—Weight decreased—Estradiol—prostate cancer	0.00207	0.00331	CcSEcCtD
Trihexyphenidyl—Vomiting—Flutamide—prostate cancer	0.00207	0.00331	CcSEcCtD
Trihexyphenidyl—Rash—Nilutamide—prostate cancer	0.00206	0.0033	CcSEcCtD
Trihexyphenidyl—Dermatitis—Nilutamide—prostate cancer	0.00206	0.00329	CcSEcCtD
Trihexyphenidyl—Rash—Flutamide—prostate cancer	0.00205	0.00328	CcSEcCtD
Trihexyphenidyl—Dermatitis—Flutamide—prostate cancer	0.00205	0.00328	CcSEcCtD
Trihexyphenidyl—Headache—Nilutamide—prostate cancer	0.00205	0.00328	CcSEcCtD
Trihexyphenidyl—Headache—Flutamide—prostate cancer	0.00204	0.00326	CcSEcCtD
Trihexyphenidyl—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00203	0.00325	CcSEcCtD
Trihexyphenidyl—Constipation—Bicalutamide—prostate cancer	0.00202	0.00323	CcSEcCtD
Trihexyphenidyl—Tension—Goserelin—prostate cancer	0.00197	0.00316	CcSEcCtD
Trihexyphenidyl—Asthenia—Cabazitaxel—prostate cancer	0.00197	0.00316	CcSEcCtD
Trihexyphenidyl—Tension—Conjugated Estrogens—prostate cancer	0.00195	0.00313	CcSEcCtD
Trihexyphenidyl—Nervousness—Goserelin—prostate cancer	0.00195	0.00313	CcSEcCtD
Trihexyphenidyl—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00195	0.00312	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Bicalutamide—prostate cancer	0.00194	0.00311	CcSEcCtD
Trihexyphenidyl—Nausea—Nilutamide—prostate cancer	0.00194	0.00311	CcSEcCtD
Trihexyphenidyl—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00194	0.0031	CcSEcCtD
Trihexyphenidyl—Nervousness—Conjugated Estrogens—prostate cancer	0.00193	0.0031	CcSEcCtD
Trihexyphenidyl—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00193	0.0031	CcSEcCtD
Trihexyphenidyl—Nausea—Flutamide—prostate cancer	0.00193	0.00309	CcSEcCtD
Trihexyphenidyl—Dizziness—Degarelix—prostate cancer	0.00193	0.00309	CcSEcCtD
Trihexyphenidyl—Weight decreased—Mitoxantrone—prostate cancer	0.00193	0.00309	CcSEcCtD
Trihexyphenidyl—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00192	0.00308	CcSEcCtD
Trihexyphenidyl—Drowsiness—Mitoxantrone—prostate cancer	0.0019	0.00304	CcSEcCtD
Trihexyphenidyl—Vision blurred—Goserelin—prostate cancer	0.00189	0.00303	CcSEcCtD
Trihexyphenidyl—Vision blurred—Conjugated Estrogens—prostate cancer	0.00188	0.003	CcSEcCtD
Trihexyphenidyl—Vomiting—Degarelix—prostate cancer	0.00186	0.00297	CcSEcCtD
Trihexyphenidyl—Rash—Degarelix—prostate cancer	0.00184	0.00295	CcSEcCtD
Trihexyphenidyl—Dermatitis—Degarelix—prostate cancer	0.00184	0.00294	CcSEcCtD
Trihexyphenidyl—Headache—Degarelix—prostate cancer	0.00183	0.00293	CcSEcCtD
Trihexyphenidyl—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00182	0.00292	CcSEcCtD
Trihexyphenidyl—Dizziness—Cabazitaxel—prostate cancer	0.00182	0.00291	CcSEcCtD
Trihexyphenidyl—Hyperkinesia—Prednisone—prostate cancer	0.00177	0.00283	CcSEcCtD
Trihexyphenidyl—Vomiting—Cabazitaxel—prostate cancer	0.00175	0.0028	CcSEcCtD
Trihexyphenidyl—Euphoric mood—Prednisone—prostate cancer	0.00174	0.00279	CcSEcCtD
Trihexyphenidyl—Nausea—Degarelix—prostate cancer	0.00173	0.00278	CcSEcCtD
Trihexyphenidyl—Headache—Cabazitaxel—prostate cancer	0.00172	0.00276	CcSEcCtD
Trihexyphenidyl—Constipation—Ethinyl Estradiol—prostate cancer	0.00171	0.00273	CcSEcCtD
Trihexyphenidyl—Asthenia—Bicalutamide—prostate cancer	0.00169	0.00271	CcSEcCtD
Trihexyphenidyl—Confusional state—Goserelin—prostate cancer	0.00165	0.00265	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.00164	0.00263	CcSEcCtD
Trihexyphenidyl—Nausea—Cabazitaxel—prostate cancer	0.00163	0.00261	CcSEcCtD
Trihexyphenidyl—Tachycardia—Goserelin—prostate cancer	0.0016	0.00256	CcSEcCtD
Trihexyphenidyl—Tachycardia—Conjugated Estrogens—prostate cancer	0.00159	0.00254	CcSEcCtD
Trihexyphenidyl—Tension—Estradiol—prostate cancer	0.00156	0.0025	CcSEcCtD
Trihexyphenidyl—Dry skin—Docetaxel—prostate cancer	0.00156	0.0025	CcSEcCtD
Trihexyphenidyl—Dizziness—Bicalutamide—prostate cancer	0.00156	0.0025	CcSEcCtD
Trihexyphenidyl—Nervousness—Estradiol—prostate cancer	0.00155	0.00248	CcSEcCtD
Trihexyphenidyl—Dry skin—Capecitabine—prostate cancer	0.00151	0.00242	CcSEcCtD
Trihexyphenidyl—Vomiting—Bicalutamide—prostate cancer	0.0015	0.0024	CcSEcCtD
Trihexyphenidyl—Rash—Bicalutamide—prostate cancer	0.00149	0.00238	CcSEcCtD
Trihexyphenidyl—Dermatitis—Bicalutamide—prostate cancer	0.00149	0.00238	CcSEcCtD
Trihexyphenidyl—Headache—Bicalutamide—prostate cancer	0.00148	0.00237	CcSEcCtD
Trihexyphenidyl—Agitation—Estradiol—prostate cancer	0.00146	0.00234	CcSEcCtD
Trihexyphenidyl—Somnolence—Goserelin—prostate cancer	0.00146	0.00234	CcSEcCtD
Trihexyphenidyl—Somnolence—Conjugated Estrogens—prostate cancer	0.00145	0.00231	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Prednisone—prostate cancer	0.00144	0.0023	CcSEcCtD
Trihexyphenidyl—Asthenia—Ethinyl Estradiol—prostate cancer	0.00143	0.00229	CcSEcCtD
Trihexyphenidyl—Constipation—Goserelin—prostate cancer	0.0014	0.00225	CcSEcCtD
Trihexyphenidyl—Nausea—Bicalutamide—prostate cancer	0.0014	0.00224	CcSEcCtD
Trihexyphenidyl—Vision blurred—Mitoxantrone—prostate cancer	0.0014	0.00224	CcSEcCtD
Trihexyphenidyl—Constipation—Conjugated Estrogens—prostate cancer	0.00139	0.00222	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Goserelin—prostate cancer	0.00135	0.00216	CcSEcCtD
Trihexyphenidyl—Dry skin—Prednisone—prostate cancer	0.00135	0.00216	CcSEcCtD
Trihexyphenidyl—Weight decreased—Docetaxel—prostate cancer	0.00133	0.00213	CcSEcCtD
Trihexyphenidyl—Dizziness—Ethinyl Estradiol—prostate cancer	0.00132	0.00211	CcSEcCtD
Trihexyphenidyl—Confusional state—Estradiol—prostate cancer	0.00131	0.0021	CcSEcCtD
Trihexyphenidyl—Weight decreased—Capecitabine—prostate cancer	0.00129	0.00207	CcSEcCtD
Trihexyphenidyl—Tachycardia—Estradiol—prostate cancer	0.00127	0.00203	CcSEcCtD
Trihexyphenidyl—Vomiting—Ethinyl Estradiol—prostate cancer	0.00127	0.00203	CcSEcCtD
Trihexyphenidyl—Rash—Ethinyl Estradiol—prostate cancer	0.00126	0.00201	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00126	0.00201	CcSEcCtD
Trihexyphenidyl—Headache—Ethinyl Estradiol—prostate cancer	0.00125	0.002	CcSEcCtD
Trihexyphenidyl—Confusional state—Mitoxantrone—prostate cancer	0.00122	0.00196	CcSEcCtD
Trihexyphenidyl—Nausea—Ethinyl Estradiol—prostate cancer	0.00118	0.0019	CcSEcCtD
Trihexyphenidyl—Tachycardia—Mitoxantrone—prostate cancer	0.00118	0.00189	CcSEcCtD
Trihexyphenidyl—Asthenia—Goserelin—prostate cancer	0.00118	0.00188	CcSEcCtD
Trihexyphenidyl—Asthenia—Conjugated Estrogens—prostate cancer	0.00117	0.00187	CcSEcCtD
Trihexyphenidyl—Somnolence—Estradiol—prostate cancer	0.00116	0.00185	CcSEcCtD
Trihexyphenidyl—Weight decreased—Prednisone—prostate cancer	0.00115	0.00184	CcSEcCtD
Trihexyphenidyl—Constipation—Estradiol—prostate cancer	0.00111	0.00178	CcSEcCtD
Trihexyphenidyl—Dizziness—Goserelin—prostate cancer	0.00109	0.00174	CcSEcCtD
Trihexyphenidyl—Somnolence—Mitoxantrone—prostate cancer	0.00108	0.00172	CcSEcCtD
Trihexyphenidyl—Dizziness—Conjugated Estrogens—prostate cancer	0.00107	0.00172	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Estradiol—prostate cancer	0.00107	0.00172	CcSEcCtD
Trihexyphenidyl—Dry skin—Epirubicin—prostate cancer	0.00105	0.00169	CcSEcCtD
Trihexyphenidyl—Vomiting—Goserelin—prostate cancer	0.00104	0.00167	CcSEcCtD
Trihexyphenidyl—Constipation—Mitoxantrone—prostate cancer	0.00104	0.00166	CcSEcCtD
Trihexyphenidyl—Rash—Goserelin—prostate cancer	0.00103	0.00166	CcSEcCtD
Trihexyphenidyl—Dermatitis—Goserelin—prostate cancer	0.00103	0.00165	CcSEcCtD
Trihexyphenidyl—Vomiting—Conjugated Estrogens—prostate cancer	0.00103	0.00165	CcSEcCtD
Trihexyphenidyl—Headache—Goserelin—prostate cancer	0.00103	0.00165	CcSEcCtD
Trihexyphenidyl—Rash—Conjugated Estrogens—prostate cancer	0.00102	0.00164	CcSEcCtD
Trihexyphenidyl—Dermatitis—Conjugated Estrogens—prostate cancer	0.00102	0.00164	CcSEcCtD
Trihexyphenidyl—Headache—Conjugated Estrogens—prostate cancer	0.00102	0.00163	CcSEcCtD
Trihexyphenidyl—Confusional state—Etoposide—prostate cancer	0.00102	0.00163	CcSEcCtD
Trihexyphenidyl—Hallucination—Prednisone—prostate cancer	0.00101	0.00162	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Mitoxantrone—prostate cancer	0.000999	0.0016	CcSEcCtD
Trihexyphenidyl—Tachycardia—Etoposide—prostate cancer	0.000984	0.00158	CcSEcCtD
Trihexyphenidyl—Dry skin—Doxorubicin—prostate cancer	0.000975	0.00156	CcSEcCtD
Trihexyphenidyl—Nausea—Goserelin—prostate cancer	0.000975	0.00156	CcSEcCtD
Trihexyphenidyl—Nausea—Conjugated Estrogens—prostate cancer	0.000965	0.00155	CcSEcCtD
Trihexyphenidyl—Vision blurred—Capecitabine—prostate cancer	0.000937	0.0015	CcSEcCtD
Trihexyphenidyl—Asthenia—Estradiol—prostate cancer	0.000933	0.00149	CcSEcCtD
Trihexyphenidyl—Weight decreased—Epirubicin—prostate cancer	0.000899	0.00144	CcSEcCtD
Trihexyphenidyl—Oxybutynin—CYP3A5—prostate cancer	0.000898	0.698	CrCbGaD
Trihexyphenidyl—Somnolence—Etoposide—prostate cancer	0.000896	0.00143	CcSEcCtD
Trihexyphenidyl—Drowsiness—Epirubicin—prostate cancer	0.000886	0.00142	CcSEcCtD
Trihexyphenidyl—Asthenia—Mitoxantrone—prostate cancer	0.00087	0.00139	CcSEcCtD
Trihexyphenidyl—Constipation—Etoposide—prostate cancer	0.000862	0.00138	CcSEcCtD
Trihexyphenidyl—Dizziness—Estradiol—prostate cancer	0.00086	0.00138	CcSEcCtD
Trihexyphenidyl—Confusional state—Docetaxel—prostate cancer	0.000845	0.00135	CcSEcCtD
Trihexyphenidyl—Vision blurred—Prednisone—prostate cancer	0.000834	0.00134	CcSEcCtD
Trihexyphenidyl—Weight decreased—Doxorubicin—prostate cancer	0.000832	0.00133	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Etoposide—prostate cancer	0.000831	0.00133	CcSEcCtD
Trihexyphenidyl—Vomiting—Estradiol—prostate cancer	0.000827	0.00132	CcSEcCtD
Trihexyphenidyl—Rash—Estradiol—prostate cancer	0.00082	0.00131	CcSEcCtD
Trihexyphenidyl—Drowsiness—Doxorubicin—prostate cancer	0.00082	0.00131	CcSEcCtD
Trihexyphenidyl—Dermatitis—Estradiol—prostate cancer	0.000819	0.00131	CcSEcCtD
Trihexyphenidyl—Confusional state—Capecitabine—prostate cancer	0.000818	0.00131	CcSEcCtD
Trihexyphenidyl—Tachycardia—Docetaxel—prostate cancer	0.000818	0.00131	CcSEcCtD
Trihexyphenidyl—Headache—Estradiol—prostate cancer	0.000815	0.0013	CcSEcCtD
Trihexyphenidyl—Agitation—Prednisone—prostate cancer	0.000814	0.0013	CcSEcCtD
Trihexyphenidyl—Tachycardia—Capecitabine—prostate cancer	0.000792	0.00127	CcSEcCtD
Trihexyphenidyl—Nausea—Estradiol—prostate cancer	0.000773	0.00124	CcSEcCtD
Trihexyphenidyl—Vomiting—Mitoxantrone—prostate cancer	0.000771	0.00123	CcSEcCtD
Trihexyphenidyl—Rash—Mitoxantrone—prostate cancer	0.000764	0.00122	CcSEcCtD
Trihexyphenidyl—Dermatitis—Mitoxantrone—prostate cancer	0.000764	0.00122	CcSEcCtD
Trihexyphenidyl—Headache—Mitoxantrone—prostate cancer	0.000759	0.00122	CcSEcCtD
Trihexyphenidyl—Somnolence—Docetaxel—prostate cancer	0.000745	0.00119	CcSEcCtD
Trihexyphenidyl—Asthenia—Etoposide—prostate cancer	0.000723	0.00116	CcSEcCtD
Trihexyphenidyl—Nausea—Mitoxantrone—prostate cancer	0.00072	0.00115	CcSEcCtD
Trihexyphenidyl—Constipation—Docetaxel—prostate cancer	0.000717	0.00115	CcSEcCtD
Trihexyphenidyl—Tachycardia—Prednisone—prostate cancer	0.000705	0.00113	CcSEcCtD
Trihexyphenidyl—Constipation—Capecitabine—prostate cancer	0.000694	0.00111	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Docetaxel—prostate cancer	0.00069	0.00111	CcSEcCtD
Trihexyphenidyl—Tension—Epirubicin—prostate cancer	0.00068	0.00109	CcSEcCtD
Trihexyphenidyl—Nervousness—Epirubicin—prostate cancer	0.000673	0.00108	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Capecitabine—prostate cancer	0.000669	0.00107	CcSEcCtD
Trihexyphenidyl—Dizziness—Etoposide—prostate cancer	0.000667	0.00107	CcSEcCtD
Trihexyphenidyl—Vision blurred—Epirubicin—prostate cancer	0.000653	0.00104	CcSEcCtD
Trihexyphenidyl—Vomiting—Etoposide—prostate cancer	0.000641	0.00103	CcSEcCtD
Trihexyphenidyl—Agitation—Epirubicin—prostate cancer	0.000636	0.00102	CcSEcCtD
Trihexyphenidyl—Rash—Etoposide—prostate cancer	0.000636	0.00102	CcSEcCtD
Trihexyphenidyl—Dermatitis—Etoposide—prostate cancer	0.000635	0.00102	CcSEcCtD
Trihexyphenidyl—Headache—Etoposide—prostate cancer	0.000632	0.00101	CcSEcCtD
Trihexyphenidyl—Tension—Doxorubicin—prostate cancer	0.000629	0.00101	CcSEcCtD
Trihexyphenidyl—Nervousness—Doxorubicin—prostate cancer	0.000622	0.000996	CcSEcCtD
Trihexyphenidyl—Constipation—Prednisone—prostate cancer	0.000618	0.000989	CcSEcCtD
Trihexyphenidyl—Vision blurred—Doxorubicin—prostate cancer	0.000604	0.000967	CcSEcCtD
Trihexyphenidyl—Asthenia—Docetaxel—prostate cancer	0.000601	0.000962	CcSEcCtD
Trihexyphenidyl—Nausea—Etoposide—prostate cancer	0.000599	0.000959	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Prednisone—prostate cancer	0.000595	0.000953	CcSEcCtD
Trihexyphenidyl—Agitation—Doxorubicin—prostate cancer	0.000589	0.000942	CcSEcCtD
Trihexyphenidyl—Asthenia—Capecitabine—prostate cancer	0.000582	0.000932	CcSEcCtD
Trihexyphenidyl—Confusional state—Epirubicin—prostate cancer	0.00057	0.000912	CcSEcCtD
Trihexyphenidyl—Dizziness—Docetaxel—prostate cancer	0.000554	0.000887	CcSEcCtD
Trihexyphenidyl—Tachycardia—Epirubicin—prostate cancer	0.000552	0.000883	CcSEcCtD
Trihexyphenidyl—Dizziness—Capecitabine—prostate cancer	0.000536	0.000859	CcSEcCtD
Trihexyphenidyl—Vomiting—Docetaxel—prostate cancer	0.000533	0.000853	CcSEcCtD
Trihexyphenidyl—Rash—Docetaxel—prostate cancer	0.000528	0.000846	CcSEcCtD
Trihexyphenidyl—Dermatitis—Docetaxel—prostate cancer	0.000528	0.000845	CcSEcCtD
Trihexyphenidyl—Confusional state—Doxorubicin—prostate cancer	0.000527	0.000844	CcSEcCtD
Trihexyphenidyl—Headache—Docetaxel—prostate cancer	0.000525	0.00084	CcSEcCtD
Trihexyphenidyl—Asthenia—Prednisone—prostate cancer	0.000518	0.00083	CcSEcCtD
Trihexyphenidyl—Vomiting—Capecitabine—prostate cancer	0.000516	0.000826	CcSEcCtD
Trihexyphenidyl—Rash—Capecitabine—prostate cancer	0.000512	0.000819	CcSEcCtD
Trihexyphenidyl—Dermatitis—Capecitabine—prostate cancer	0.000511	0.000818	CcSEcCtD
Trihexyphenidyl—Tachycardia—Doxorubicin—prostate cancer	0.00051	0.000817	CcSEcCtD
Trihexyphenidyl—Headache—Capecitabine—prostate cancer	0.000508	0.000813	CcSEcCtD
Trihexyphenidyl—Somnolence—Epirubicin—prostate cancer	0.000502	0.000804	CcSEcCtD
Trihexyphenidyl—Nausea—Docetaxel—prostate cancer	0.000498	0.000797	CcSEcCtD
Trihexyphenidyl—Constipation—Epirubicin—prostate cancer	0.000483	0.000774	CcSEcCtD
Trihexyphenidyl—Nausea—Capecitabine—prostate cancer	0.000482	0.000771	CcSEcCtD
Trihexyphenidyl—Dizziness—Prednisone—prostate cancer	0.000478	0.000765	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Epirubicin—prostate cancer	0.000466	0.000745	CcSEcCtD
Trihexyphenidyl—Somnolence—Doxorubicin—prostate cancer	0.000465	0.000744	CcSEcCtD
Trihexyphenidyl—Vomiting—Prednisone—prostate cancer	0.000459	0.000735	CcSEcCtD
Trihexyphenidyl—Rash—Prednisone—prostate cancer	0.000456	0.000729	CcSEcCtD
Trihexyphenidyl—Dermatitis—Prednisone—prostate cancer	0.000455	0.000729	CcSEcCtD
Trihexyphenidyl—Headache—Prednisone—prostate cancer	0.000453	0.000725	CcSEcCtD
Trihexyphenidyl—Constipation—Doxorubicin—prostate cancer	0.000447	0.000716	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Doxorubicin—prostate cancer	0.000431	0.00069	CcSEcCtD
Trihexyphenidyl—Nausea—Prednisone—prostate cancer	0.000429	0.000687	CcSEcCtD
Trihexyphenidyl—Asthenia—Epirubicin—prostate cancer	0.000405	0.000649	CcSEcCtD
Trihexyphenidyl—Oxybutynin—CYP3A4—prostate cancer	0.000389	0.302	CrCbGaD
Trihexyphenidyl—Asthenia—Doxorubicin—prostate cancer	0.000375	0.000601	CcSEcCtD
Trihexyphenidyl—Dizziness—Epirubicin—prostate cancer	0.000374	0.000598	CcSEcCtD
Trihexyphenidyl—Vomiting—Epirubicin—prostate cancer	0.000359	0.000575	CcSEcCtD
Trihexyphenidyl—Rash—Epirubicin—prostate cancer	0.000356	0.00057	CcSEcCtD
Trihexyphenidyl—Dermatitis—Epirubicin—prostate cancer	0.000356	0.00057	CcSEcCtD
Trihexyphenidyl—Headache—Epirubicin—prostate cancer	0.000354	0.000567	CcSEcCtD
Trihexyphenidyl—Dizziness—Doxorubicin—prostate cancer	0.000346	0.000554	CcSEcCtD
Trihexyphenidyl—Nausea—Epirubicin—prostate cancer	0.000336	0.000537	CcSEcCtD
Trihexyphenidyl—Vomiting—Doxorubicin—prostate cancer	0.000332	0.000532	CcSEcCtD
Trihexyphenidyl—Rash—Doxorubicin—prostate cancer	0.00033	0.000528	CcSEcCtD
Trihexyphenidyl—Dermatitis—Doxorubicin—prostate cancer	0.000329	0.000527	CcSEcCtD
Trihexyphenidyl—Headache—Doxorubicin—prostate cancer	0.000328	0.000524	CcSEcCtD
Trihexyphenidyl—Nausea—Doxorubicin—prostate cancer	0.000311	0.000497	CcSEcCtD
Trihexyphenidyl—CHRM1—Signaling Pathways—ITGB3—prostate cancer	3.24e-05	0.000127	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—KRAS—prostate cancer	3.24e-05	0.000127	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ITGB3—prostate cancer	3.23e-05	0.000127	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ITGB3—prostate cancer	3.2e-05	0.000126	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MAP2K1—prostate cancer	3.19e-05	0.000125	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CD—prostate cancer	3.17e-05	0.000125	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—FGF2—prostate cancer	3.17e-05	0.000125	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	3.16e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	3.15e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ERBB3—prostate cancer	3.14e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—PIK3CA—prostate cancer	3.14e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGFR2—prostate cancer	3.14e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SERPINE1—prostate cancer	3.13e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ERBB3—prostate cancer	3.13e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGFR2—prostate cancer	3.13e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—NOS3—prostate cancer	3.13e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	3.12e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ERBB3—prostate cancer	3.1e-05	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—KRAS—prostate cancer	3.1e-05	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGFR2—prostate cancer	3.1e-05	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—JAK2—prostate cancer	3.04e-05	0.000119	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—FGF2—prostate cancer	3.03e-05	0.000119	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CG—prostate cancer	3.03e-05	0.000119	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL2—prostate cancer	3.02e-05	0.000119	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL2—prostate cancer	3.01e-05	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TERT—prostate cancer	3.01e-05	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TERT—prostate cancer	3e-05	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—NOS3—prostate cancer	2.99e-05	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL2—prostate cancer	2.99e-05	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—PIK3CA—prostate cancer	2.98e-05	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TERT—prostate cancer	2.97e-05	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MDM2—prostate cancer	2.97e-05	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—ERBB2—prostate cancer	2.92e-05	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—JAK2—prostate cancer	2.91e-05	0.000114	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CB—prostate cancer	2.88e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—HIF1A—prostate cancer	2.88e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—HIF1A—prostate cancer	2.87e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—INS—prostate cancer	2.86e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—PIK3CA—prostate cancer	2.85e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—HIF1A—prostate cancer	2.84e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MDM2—prostate cancer	2.84e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LEP—prostate cancer	2.81e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CREBBP—prostate cancer	2.81e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LEP—prostate cancer	2.8e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—ERBB2—prostate cancer	2.8e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CAV1—prostate cancer	2.79e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CAV1—prostate cancer	2.78e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LEP—prostate cancer	2.78e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CXCL8—prostate cancer	2.77e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CB—prostate cancer	2.76e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KDR—prostate cancer	2.76e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CAV1—prostate cancer	2.75e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KDR—prostate cancer	2.75e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KDR—prostate cancer	2.72e-05	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CDKN1B—prostate cancer	2.71e-05	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ESR1—prostate cancer	2.69e-05	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—AKT1—prostate cancer	2.68e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ESR1—prostate cancer	2.68e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CD—prostate cancer	2.66e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CXCL8—prostate cancer	2.65e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CASP3—prostate cancer	2.65e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ESR1—prostate cancer	2.65e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL2—prostate cancer	2.65e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—prostate cancer	2.64e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—BAD—prostate cancer	2.62e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—BAD—prostate cancer	2.61e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CDKN1B—prostate cancer	2.59e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—BAD—prostate cancer	2.59e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCND1—prostate cancer	2.58e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—AKT1—prostate cancer	2.56e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CTNNB1—prostate cancer	2.56e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CASP3—prostate cancer	2.54e-05	9.99e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	2.54e-05	9.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APC—prostate cancer	2.54e-05	9.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL2—prostate cancer	2.54e-05	9.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APC—prostate cancer	2.53e-05	9.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	2.53e-05	9.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—prostate cancer	2.52e-05	9.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—NOS3—prostate cancer	2.51e-05	9.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EGF—prostate cancer	2.51e-05	9.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS1—prostate cancer	2.51e-05	9.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MMP9—prostate cancer	2.51e-05	9.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	2.51e-05	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APC—prostate cancer	2.51e-05	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS1—prostate cancer	2.5e-05	9.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EGF—prostate cancer	2.5e-05	9.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CDKN1A—prostate cancer	2.5e-05	9.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PTEN—prostate cancer	2.49e-05	9.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EGF—prostate cancer	2.48e-05	9.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS1—prostate cancer	2.48e-05	9.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCND1—prostate cancer	2.47e-05	9.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	2.45e-05	9.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—GSK3B—prostate cancer	2.44e-05	9.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—AKT1—prostate cancer	2.43e-05	9.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—GSK3B—prostate cancer	2.43e-05	9.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—GSK3B—prostate cancer	2.4e-05	9.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—INS—prostate cancer	2.4e-05	9.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MMP9—prostate cancer	2.4e-05	9.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—INS—prostate cancer	2.4e-05	9.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	2.39e-05	9.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PTEN—prostate cancer	2.39e-05	9.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—EP300—prostate cancer	2.38e-05	9.35e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—INS—prostate cancer	2.37e-05	9.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CREBBP—prostate cancer	2.35e-05	9.25e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CREBBP—prostate cancer	2.35e-05	9.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—AKT1—prostate cancer	2.33e-05	9.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF1—prostate cancer	2.32e-05	9.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CREBBP—prostate cancer	2.32e-05	9.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CB—prostate cancer	2.32e-05	9.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF1—prostate cancer	2.32e-05	9.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—EGFR—prostate cancer	2.31e-05	9.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SRC—prostate cancer	2.31e-05	9.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—EGFR—prostate cancer	2.31e-05	9.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTGS2—prostate cancer	2.3e-05	9.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF1—prostate cancer	2.29e-05	9.02e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—EGFR—prostate cancer	2.28e-05	8.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—EP300—prostate cancer	2.28e-05	8.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—VEGFA—prostate cancer	2.25e-05	8.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	2.25e-05	8.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	2.24e-05	8.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	2.23e-05	8.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—STAT3—prostate cancer	2.23e-05	8.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	2.22e-05	8.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	2.22e-05	8.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SRC—prostate cancer	2.21e-05	8.7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	2.21e-05	8.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	2.21e-05	8.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	2.2e-05	8.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	2.2e-05	8.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	2.2e-05	8.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—KRAS—prostate cancer	2.18e-05	8.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	2.18e-05	8.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	2.18e-05	8.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—KRAS—prostate cancer	2.18e-05	8.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—KRAS—prostate cancer	2.16e-05	8.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—VEGFA—prostate cancer	2.16e-05	8.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGF2—prostate cancer	2.14e-05	8.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—STAT3—prostate cancer	2.14e-05	8.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGF2—prostate cancer	2.13e-05	8.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGF2—prostate cancer	2.11e-05	8.29e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOS3—prostate cancer	2.11e-05	8.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOS3—prostate cancer	2.1e-05	8.26e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOS3—prostate cancer	2.08e-05	8.18e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MYC—prostate cancer	2.07e-05	8.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TGFB1—prostate cancer	2.07e-05	8.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—JAK2—prostate cancer	2.05e-05	8.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—JAK2—prostate cancer	2.04e-05	8.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—EGFR—prostate cancer	2.03e-05	7.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—JAK2—prostate cancer	2.02e-05	7.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	2.01e-05	7.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTEN—prostate cancer	2e-05	7.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	2e-05	7.87e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MDM2—prostate cancer	2e-05	7.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MDM2—prostate cancer	1.99e-05	7.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MYC—prostate cancer	1.98e-05	7.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	1.98e-05	7.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TGFB1—prostate cancer	1.98e-05	7.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MDM2—prostate cancer	1.97e-05	7.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.97e-05	7.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ERBB2—prostate cancer	1.96e-05	7.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ERBB2—prostate cancer	1.95e-05	7.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.95e-05	7.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—EGFR—prostate cancer	1.94e-05	7.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	1.94e-05	7.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	1.92e-05	7.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—KRAS—prostate cancer	1.91e-05	7.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—EP300—prostate cancer	1.91e-05	7.51e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.87e-05	7.35e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CXCL8—prostate cancer	1.86e-05	7.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CXCL8—prostate cancer	1.85e-05	7.25e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—KRAS—prostate cancer	1.83e-05	7.21e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.83e-05	7.18e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	1.82e-05	7.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.81e-05	7.1e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	1.8e-05	7.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	1.8e-05	7.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.79e-05	7.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL2—prostate cancer	1.79e-05	7.02e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CASP3—prostate cancer	1.78e-05	7.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	1.78e-05	7.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL2—prostate cancer	1.78e-05	7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.78e-05	6.99e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—prostate cancer	1.77e-05	6.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CASP3—prostate cancer	1.77e-05	6.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL2—prostate cancer	1.76e-05	6.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	1.76e-05	6.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—prostate cancer	1.75e-05	6.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.74e-05	6.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCND1—prostate cancer	1.74e-05	6.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.72e-05	6.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	1.72e-05	6.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCND1—prostate cancer	1.72e-05	6.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	1.7e-05	6.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TP53—prostate cancer	1.7e-05	6.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MMP9—prostate cancer	1.69e-05	6.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MMP9—prostate cancer	1.69e-05	6.63e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.68e-05	6.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	1.68e-05	6.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.68e-05	6.61e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.68e-05	6.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.68e-05	6.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.67e-05	6.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.66e-05	6.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.66e-05	6.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.64e-05	6.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.63e-05	6.43e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TP53—prostate cancer	1.63e-05	6.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—AKT1—prostate cancer	1.62e-05	6.36e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EP300—prostate cancer	1.6e-05	6.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EP300—prostate cancer	1.6e-05	6.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EP300—prostate cancer	1.58e-05	6.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SRC—prostate cancer	1.56e-05	6.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—prostate cancer	1.56e-05	6.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SRC—prostate cancer	1.55e-05	6.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SRC—prostate cancer	1.54e-05	6.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.52e-05	5.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—VEGFA—prostate cancer	1.51e-05	5.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.5e-05	5.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.5e-05	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—STAT3—prostate cancer	1.5e-05	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—prostate cancer	1.49e-05	5.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.48e-05	5.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT1—prostate cancer	1.44e-05	5.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CA—prostate cancer	1.41e-05	5.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MYC—prostate cancer	1.4e-05	5.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFB1—prostate cancer	1.39e-05	5.48e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MYC—prostate cancer	1.39e-05	5.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFB1—prostate cancer	1.39e-05	5.46e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MYC—prostate cancer	1.38e-05	5.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT1—prostate cancer	1.38e-05	5.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.38e-05	5.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EGFR—prostate cancer	1.37e-05	5.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EGFR—prostate cancer	1.36e-05	5.35e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.35e-05	5.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KRAS—prostate cancer	1.29e-05	5.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KRAS—prostate cancer	1.29e-05	5.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.27e-05	5.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	1.19e-05	4.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	1.18e-05	4.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	1.17e-05	4.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AKT1—prostate cancer	1.15e-05	4.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TP53—prostate cancer	1.15e-05	4.51e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TP53—prostate cancer	1.14e-05	4.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TP53—prostate cancer	1.13e-05	4.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—prostate cancer	1.05e-05	4.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—prostate cancer	1.05e-05	4.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—prostate cancer	1.04e-05	4.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT1—prostate cancer	9.69e-06	3.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT1—prostate cancer	9.66e-06	3.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT1—prostate cancer	9.56e-06	3.76e-05	CbGpPWpGaD
